Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1175548

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how patient organisations were recruited to the 11 NICE methods review task and finish groups.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11444
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The following patient groups are currently involved across the programme of task and finish groups. The National Institute for Health and Care Excellence (NICE) has advised that it continues to seek further members for the task and finish groups, and a full list of members is still to be finalised.</p><p>- Alzheimer's Research UK;</p><p>- Breast Cancer Now;</p><p>- Cancer52;</p><p>- Cystic Fibrosis Trust ;</p><p>- Diabetes UK;</p><p>- Genetic Alliance UK;</p><p>- Leukaemia CARE;</p><p>- Multiple Sclerosis Society;</p><p>- Muscular Dystrophy UK;</p><p>- Myeloma UK;</p><p>- Neuroendocrine Cancer UK;</p><p>- Prostate cancer UK; and</p><p>- Sarcoma UK.</p><p> </p><p>In recruiting patient organisations to the NICE methods review task and finish groups, patients on the methods working group were asked to nominate representatives with a range of experience. Additional representatives were nominated by NICE where particular expertise or input was required. The organisations involved in the task and finish groups cover a broad spectrum of disease areas including cancer, non-cancer and rare diseases.<strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11443 question first answered 06/02/2020 17:20:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175549

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the NICE methods review task and finish groups will take to consult with the wider health charity sector.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11445
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The National Institute for Heath and Care Excellence (NICE) has advised that a six week public consultation on the proposals for changing its methods and processes will take place this summer. We understand that further work on the timetable is in progress and will be communicated in due course.</p><p>The wider health charity sector will have an opportunity to review the proposals for change from the task and finish groups during this consultation.</p><p>NICE also held a webinar with stakeholders in November 2019 to share how and why health technology evaluation is changing and what it means for patients. The webinar is available on the NICE website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE staff have also participated in a number of events to engage with the patient community, including the charity sector and about the methods review.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11446 question first answered 06/02/2020 17:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175550

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the publication of the full consultation on the proposed reforms to NICE methods and processes.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11446
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The National Institute for Heath and Care Excellence (NICE) has advised that a six week public consultation on the proposals for changing its methods and processes will take place this summer. We understand that further work on the timetable is in progress and will be communicated in due course.</p><p>The wider health charity sector will have an opportunity to review the proposals for change from the task and finish groups during this consultation.</p><p>NICE also held a webinar with stakeholders in November 2019 to share how and why health technology evaluation is changing and what it means for patients. The webinar is available on the NICE website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE staff have also participated in a number of events to engage with the patient community, including the charity sector and about the methods review.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11445 question first answered 06/02/2020 17:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1242957

	registered interest
	date	13/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to develop advice for people who were previously shielding tailored to the risk associated with their particular disease, including different types of blood cancer, in the event that further restrictions are introduced as a result of the covid-19 outbreak.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	102671
	answer	answer is ministerial correction date of answer 23/10/2020 answer text <p>Shielding was paused on 1 August 2020 in England; however, it is important that clinically extremely vulnerable people continue to take extra care, particularly as infection rates rise again. On 13 October, the Government published new guidance to the clinically extremely vulnerable that advises additional things they are advised to do to keep themselves safe at each local COVID alert level.</p><p>In the future, the Government will only reintroduce shielding advice in the very worst affected areas and for a limited period of time. This decision will be based on advice from the Chief Medical Officer, informed by local public health experts.</p><p>The National Health Service is continuing to maintain the shielded patient list, allowing us to maintain targeted advice and support to those who are most vulnerable and to change advice and support if necessary. General practitioners and hospital clinicians remain able to add people to the list, based on clinical judgement and an assessment of an individual’s needs.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/10/2020 13:37:18 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1243368

	registered interest
	date	14/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Multiple Myeloma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when assessment he has made of the timescale for the approval of lenalidomide as a maintenance drug for post stem cell transplant treatment of Myeloma.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	103426
	answer	answer is ministerial correction date of answer 22/10/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance on lenalidomide for the maintenance treatment of multiple myeloma after autologous stem cell transplantation.</p><p>NICE expects to publish final guidance on lenalidomide in January 2021.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2020 09:38:06 answering member 4380 label Biography information for Jo Churchill previous answer version 55271 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1282056

	registered interest
	date	29/01/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of prioritising for covid-19 vaccination people who live with those who are clinically extremely vulnerable and who are suffering from blood cancer.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	145735
	answer	answer is ministerial correction date of answer 16/02/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) are the independent experts who advise the Government on which vaccine/s the United Kingdom should use and provide advice on prioritisation at a population level. The JCVI has advised that the first priorities for any COVID-19 vaccination programme should be the prevention of COVID-19 mortality and the protection of health and social care staff and systems. Therefore, in line with the recommendations of the JCVI, the vaccine will be initially rolled out to the priority groups.</p><p> </p><p>This includes care home residents and staff, people over 80 years old and health and care workers, then to the rest of the population in order of age and risk, including those who are clinically extremely vulnerable and those aged 16-64 years old with certain underlying health conditions. Individuals with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment are considered clinically extremely vulnerable and will be eligible for a vaccine. Anyone with a history of haematological malignancy should be offered a vaccination at priority group six.</p><p> </p><p>Consideration has been given to vaccination of household contacts of immunosuppressed individuals. However, at this time there is no data on the size of the effect of COVID-19 vaccines on transmission. Evidence is expected to accrue during the course of the vaccine programme and until that time the JCVI is not in a position to advise vaccination solely on the basis of indirect protection.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 148853 question first answered 16/02/2021 10:02:29 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 79921 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	394 label Biography information for Mr Clive Betts

1362647

	registered interest
	date	22/10/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, who in the NHS is responsible for advising patients who have a compromised immune system that they are eligible for a third dose of a covid-19 vaccine; and what are arrangements for patients to receive a third dose of vaccine.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	61106
	answer	answer is ministerial correction date of answer 13/12/2021 answer text <p>A specialist or clinician should advise whether a patient fulfils the eligibility criteria for severe immunosuppression and on the timing of any third primary dose of COVID-19 vaccination. NHS England and NHS Improvement are developing tailored communications for specialists caring for each group of eligible patients. This will include template referral letters for clinicians to signpost where patients can receive their COVID-19 vaccination.</p><p>If a vaccination cannot be offered at a hospital at the time of the patient’s visit, they will receive a letter from their consultant to access a vaccination at an alternative clinic. If a patient has already received a letter from their consultant or general practitioner advising on when they should receive their third primary dose, this can be presented at a walk-in vaccination site. Vaccinators require this letter to administer the dose. Any patient who has not yet been contacted but may be eligible for a third primary dose should contact their consultant.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 13/12/2021 10:15:06 answering member 4447 label Biography information for Maggie Throup previous answer version 28174 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	394 label Biography information for Mr Clive Betts

1362648

	registered interest
	date	22/10/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the recommended time is between patients with compromised immune systems receiving a third dose of covid-19 vaccine and receiving a booster dose of that vaccine.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	61107
	answer	answer is ministerial correction date of answer 06/12/2021 answer text <p>On 29 November, the Joint Committee on Vaccination and Immunisation advised that severely immunosuppressed individuals who have completed their primary course of three doses should be offered a booster vaccination with a minimum of three months between the third primary and booster dose. Those who have not yet received their third dose may be given the third dose now to avoid further delay. A further booster dose can be given in three months, in line with the clinical advice on optimal timing. The Government has accepted this advice.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 06/12/2021 16:48:36 answering member 4447 label Biography information for Maggie Throup previous answer version 28178 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	394 label Biography information for Mr Clive Betts

1381725

	registered interest
	date	24/11/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with a compromised immune system (a) who are eligible for a third dose of the covid-19 vaccine, (b) who are eligible and have been contacted regarding the third dose and (c) who have been contacted and have received the third dose; and how many of those in (a), (b) and (c) have blood cancer.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	80905
	answer	answer is ministerial correction date of answer 02/02/2022 answer text <p>COVID-19 vaccination with a third primary dose for individuals with severe immunosuppression, including eligible patients with blood cancer, commenced on 13 September 2021. NHS England and NHS Improvement identified approximately 504,000 people who may be eligible, who were contacted by text and letter to advise them to discuss options with their clinician. All those eligible have been offered a third primary dose of the vaccine.</p><p>As of 20 December 2021, 87.7% of individuals identified as severely immunosuppressed have received a third primary COVID-19 vaccination in England. These figures are updated on an ad-hoc basis. Information on the number of these patients with blood cancer is not held centrally.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 02/02/2022 11:18:02 answering member 4447 label Biography information for Maggie Throup previous answer version 35921 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	394 label Biography information for Mr Clive Betts

1463693

	registered interest
	date	17/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to notify immunocompromised people who are eligible for a covid-19 spring booster vaccination; and which part of the NHS is responsible for informing those people.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	3471
	answer	answer is ministerial correction date of answer 13/06/2022 answer text <p>Individuals aged 12 years old and over who are immunosuppressed are eligible to receive a spring booster dose. Local National Health Service systems are responsible for inviting eligible individuals with appointments available online through the National Booking Service or via 119.</p><p>The NHS and charity and community leaders have published an open letter to encourage people with a weakened immune system to receive their COVID-19 vaccinations, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/2022/05/open-letter-from-nhs-charity-and-community-leaders-to-people-with-a-weakened-immune-system/" target="_blank">https://www.england.nhs.uk/2022/05/open-letter-from-nhs-charity-and-community-leaders-to-people-with-a-weakened-immune-system/</a></p> answering member constituency Erewash answering member printed Maggie Throup question first answered 13/06/2022 16:07:34 answering member 4447 label Biography information for Maggie Throup previous answer version 2202 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	394 label Biography information for Mr Clive Betts